Literature DB >> 22123219

Current management and treatment strategies for breast cancer.

John H Howard1, Kirby I Bland.   

Abstract

PURPOSE OF REVIEW: Breast cancer is the most common malignancy in women in the United States and the second most common cause of cancer death in women. This review will focus on the current and clinically relevant recommendations for breast cancer diagnosis, staging, and treatment. RECENT
FINDINGS: Screening for breast cancer is based on patient history, exam, mammography, and ultrasound. In select patient populations, MRI adds additional detection benefit. Once pathology is found, nipple-sparing mastectomy is felt to be an oncologically well tolerated procedure for both ductal carcinoma in situ and invasive tumors in properly selected patients. Prophylactic mastectomy rates are increasing despite no clear survival benefit. Sentinel lymph node biopsy continues to be the staging procedure of choice, but data are available that completion axillary dissection for a positive sentinel node may not affect outcomes.
SUMMARY: Strategies for caring for breast cancer patients continue to evolve. Multiple variables including genetic predisposition, disease burden, tumor markers, receptor status, and patient preference are integral to the decision making for each individual patient.

Entities:  

Mesh:

Year:  2012        PMID: 22123219     DOI: 10.1097/GCO.0b013e32834da4b1

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  17 in total

Review 1.  Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1.

Authors:  Rohit Sharma; Rohini Sharma; Tejinder Pal Khaket; Chanchala Dutta; Bornisha Chakraborty; Tapan Kumar Mukherjee
Journal:  Cell Oncol (Dordr)       Date:  2017-05-22       Impact factor: 6.730

2.  Sleep disturbance, cytokines, and fatigue in women with ovarian cancer.

Authors:  Lauren Clevenger; Andrew Schrepf; Desire Christensen; Koen DeGeest; David Bender; Amina Ahmed; Michael J Goodheart; Frank Penedo; David M Lubaroff; Anil K Sood; Susan K Lutgendorf
Journal:  Brain Behav Immun       Date:  2012-04-21       Impact factor: 7.217

3.  Xanthatin, a novel potent inhibitor of VEGFR2 signaling, inhibits angiogenesis and tumor growth in breast cancer cells.

Authors:  Yao Yu; Jing Yu; Chong Gang Pei; Yun Yan Li; Ping Tu; Gui Ping Gao; Yi Shao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  Polymorphisms of glutathione S-transferase π 1 and toll-like receptors 2 and 9: Association with breast cancer susceptibility.

Authors:  Mohammad F Al-Harras; Maha E Houssen; Mohamed E Shaker; Kamel Farag; Omar Farouk; Rehan Monir; Rasha El-Mahdy; Ekbal M Abo-Hashem
Journal:  Oncol Lett       Date:  2016-01-28       Impact factor: 2.967

5.  Increased copy number of the DLX4 homeobox gene in breast axillary lymph node metastasis.

Authors:  Clarissa Torresan; Márcia M C Oliveira; Silma R F Pereira; Enilze M S F Ribeiro; Catalin Marian; Yuriy Gusev; Rubens S Lima; Cicero A Urban; Patricia E Berg; Bassem R Haddad; Iglenir J Cavalli; Luciane R Cavalli
Journal:  Cancer Genet       Date:  2014-05-02

6.  Serum peptidome patterns of breast cancer based on magnetic bead separation and mass spectrometry analysis.

Authors:  Nai-Jun Fan; Chun-Fang Gao; Guang Zhao; Xiu-Li Wang; Qing-Yin Liu
Journal:  Diagn Pathol       Date:  2012-04-20       Impact factor: 2.644

7.  Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions.

Authors:  Sebastian Kuger; Emre Cörek; Bülent Polat; Ulrike Kämmerer; Michael Flentje; Cholpon S Djuzenova
Journal:  Breast Cancer (Auckl)       Date:  2014-03-16

Review 8.  The importance of autophagy regulation in breast cancer development and treatment.

Authors:  Joanna Magdalena Zarzynska
Journal:  Biomed Res Int       Date:  2014-09-17       Impact factor: 3.411

9.  Overexpression of p65 attenuates celecoxib-induced cell death in MDA-MB-231 human breast cancer cell line.

Authors:  Ling Wang; Fubiao Kang; Jie Li; Jing Zhang; Baoen Shan
Journal:  Cancer Cell Int       Date:  2013-02-12       Impact factor: 5.722

10.  The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer.

Authors:  Mark A Wade; Dominic Jones; Laura Wilson; Jacqueline Stockley; Kelly Coffey; Craig N Robson; Luke Gaughan
Journal:  Nucleic Acids Res       Date:  2014-12-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.